Moderna Presents Promising Flu Vaccine Data at IDWeek 2025

Moderna, Inc. has unveiled new data on two investigational influenza vaccine candidates at IDWeek 2025 in Atlanta. The mRNA-1010, targeting seasonal flu, showed a relative vaccine efficacy (rVE) of 26.6% compared to standard vaccines. It effectively prevented medically-attended influenza in adults aged 50 and above with an rVE of 33.7%. The vaccine was well-tolerated, with mild side effects like injection site pain and fatigue.

For the H5N1 pandemic flu, mRNA-1018 demonstrated strong immunogenicity in a Phase 1/2 study involving adults 18 years and older. Post-vaccination, 97.8% achieved protective immune responses, maintaining seroprotective titers in 70.6% of participants after six months.

The data presented underscores Moderna's continued innovation in mRNA vaccine technology, aiming to enhance influenza prevention amid global health challenges.